Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HIMABINDU R REDDY

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1780658708
CMS profile
217235
Location
FORT WORTH, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$3,751.57

178 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,751.57 178

By paying entity

PY2025 · entire year · sorted by reported total

Page 4 of 4; records 151–178 of 178 matching records. This page contains 28 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HIMABINDU R REDDY

NPI 1780658708 · CMS profile ID 217235

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

FORT WORTH, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–178 of 178 matching records. This page contains 28 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1780658708?year=2025&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HIMABINDU R REDDY, NPI 1780658708, CMS profile ID 217235. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–178 of 178 matching records. This page contains 28 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1780658708?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). HIMABINDU R REDDY, NPI 1780658708, CMS profile ID 217235. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–178 of 178 matching records. This page contains 28 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1780658708?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
HIMABINDU R REDDY, NPI 1780658708, CMS profile ID 217235, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–178 of 178 matching records. This page contains 28 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1780658708?year=2025&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

178 matching records · $3,751.57 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 178 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–178 of 178.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $25.4302/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203802413 CMS
GENZYME CORPORATION $26.1202/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233374934 CMS
Novartis Pharmaceuticals Corporation $16.0302/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200560921 CMS
Amgen Inc. $8.3502/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227211564 CMS
Janssen Biotech, Inc. $125.1302/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175027280 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $19.8202/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222983177 CMS
AstraZeneca Pharmaceuticals LP $17.7502/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206400543 CMS
Janssen Biotech, Inc. $26.0402/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175029128 CMS
PFIZER INC. $16.0602/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231356394 CMS
Alvogen Inc $13.7502/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1209952764 CMS
Amgen Inc. $22.0302/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228657071 CMS
GlaxoSmithKline, LLC. $20.5302/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191216255 CMS
ABBVIE INC. $18.4602/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203802407 CMS
E.R. Squibb & Sons, L.L.C. $19.6002/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184492239 CMS
Organon LLC $29.2701/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1237773744 CMS
Fidia Pharma USA Inc. $24.4701/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1185427084 CMS
Amgen Inc. $24.3801/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228657111 CMS
ABBVIE INC. $12.5701/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203802400 CMS
ABBVIE INC. $24.4501/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203802394 CMS
GENZYME CORPORATION $31.4601/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233374924 CMS
PFIZER INC. $25.3501/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231137137 CMS
UCB, Inc. $30.3101/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224749135 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $30.6501/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222983175 CMS
AstraZeneca Pharmaceuticals LP $17.7501/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207003948 CMS
GlaxoSmithKline, LLC. $20.3801/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191130891 CMS
PFIZER INC. $17.1101/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231351529 CMS
ABBVIE INC. $25.3601/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203802388 CMS
Amgen Inc. $32.9001/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228657061 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $20,468.69 61
PY2020 $4,878.29 10
PY2021 $1,915.50 9
PY2022 $417.69 18
PY2023 $2,527.11 32
PY2024 $9,464.58 166
PY2025 $3,751.57 178

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $239,386.44 94
PY2024 Recipient $20,014.46 2
PY2024 Principal investigator $20,335.44 2
PY2022 Recipient $234.00 1
PY2022 Principal investigator $123,163.17 4
PY2021 Recipient $1,315.65 2
PY2021 Principal investigator $297,697.89 8
PY2020 Recipient $3,999.90 1
PY2020 Principal investigator $139,982.50 11
PY2019 Recipient $360.00 1
PY2019 Principal investigator $8,901.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

94 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,966.60 12/19/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223290030
Principal investigator 1 SANOFI US SERVICES INC. $600.00 12/15/2025 Non-covered Recipient Entity
Arizona Arthritis Rheumatology Research PLLC
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226083223
Principal investigator 1 ARGENX US, INC. $600.00 12/12/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146137
Principal investigator 1 ARGENX US, INC. $4,702.00 11/20/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146148
Principal investigator 1 ARGENX US, INC. $1,702.00 11/20/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146156
Principal investigator 1 ARGENX US, INC. $4,402.00 11/20/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146160
Principal investigator 1 ARGENX US, INC. $4,402.00 11/20/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146163
Principal investigator 1 ARGENX US, INC. $620.00 11/20/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146209
Principal investigator 1 ARGENX US, INC. $1,009.00 11/03/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146192
Principal investigator 1 ARGENX US, INC. $375.00 11/03/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146194
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,966.60 11/03/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223287929
Principal investigator 1 ARGENX US, INC. $1,702.00 10/20/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146140
Principal investigator 1 ARGENX US, INC. $4,651.00 10/20/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146144
Principal investigator 1 ARGENX US, INC. $620.00 10/20/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146211
Principal investigator 1 ARGENX US, INC. $3,336.00 10/20/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146225
Principal investigator 1 GlaxoSmithKline, LLC. $162.00 10/08/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS RHEUMATOLOGY ASSOCIATES PC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192140638
Principal investigator 1 ARGENX US, INC. $4,402.00 10/02/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146102
Principal investigator 1 ARGENX US, INC. $4,402.00 10/02/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146106
Principal investigator 1 ARGENX US, INC. $5,261.00 10/02/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146110
Principal investigator 1 ARGENX US, INC. $4,402.00 10/02/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146115
Principal investigator 1 ARGENX US, INC. $5,261.00 10/02/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146120
Principal investigator 1 ARGENX US, INC. $1,782.00 10/02/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146125
Principal investigator 1 ARGENX US, INC. $4,402.00 10/02/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146129
Principal investigator 1 ARGENX US, INC. $4,402.00 10/02/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146133
Principal investigator 1 ARGENX US, INC. $4,702.00 10/02/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146151
Principal investigator 1 ARGENX US, INC. $620.00 10/02/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146167
Principal investigator 1 ARGENX US, INC. $620.00 10/02/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146171
Principal investigator 1 ARGENX US, INC. $620.00 10/02/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146174
Principal investigator 1 ARGENX US, INC. $620.00 10/02/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146179
Principal investigator 1 ARGENX US, INC. $620.00 10/02/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146183
Principal investigator 1 ARGENX US, INC. $620.00 10/02/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146187
Principal investigator 1 ARGENX US, INC. $1,620.00 10/02/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146199
Principal investigator 1 ARGENX US, INC. $1,620.00 10/02/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146202
Principal investigator 1 ARGENX US, INC. $1,620.00 10/02/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146206
Principal investigator 1 ARGENX US, INC. $1,702.00 10/02/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146215
Principal investigator 1 ARGENX US, INC. $1,702.00 10/02/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146219
Principal investigator 1 ARGENX US, INC. $3,336.00 10/02/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146223
Principal investigator 1 ARGENX US, INC. $5,261.00 10/02/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146229
Principal investigator 1 ARGENX US, INC. $1,782.00 10/02/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146233
Principal investigator 1 ARGENX US, INC. $1,782.00 10/02/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146238
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $50.00 10/01/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223286047
Principal investigator 1 GlaxoSmithKline, LLC. $3,500.00 09/17/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS RHEUMATOLOGY ASSOCIATES PC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192140632
Principal investigator 1 ARGENX US, INC. $375.00 09/03/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146630
Principal investigator 1 ARGENX US, INC. $324.00 09/03/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146638
Principal investigator 1 ARGENX US, INC. $1,009.00 09/03/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146649
Principal investigator 1 ARGENX US, INC. $176.00 09/03/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146667
Principal investigator 1 ARGENX US, INC. $176.00 09/03/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146671
Principal investigator 1 GlaxoSmithKline, LLC. $2,634.00 09/03/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS RHEUMATOLOGY ASSOCIATES PC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192140620
Principal investigator 1 GlaxoSmithKline, LLC. $600.00 09/03/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS RHEUMATOLOGY ASSOCIATES PC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192140645
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,966.60 09/02/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223284695
Principal investigator 1 ARGENX US, INC. $1,009.00 08/07/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146620
Principal investigator 1 ARGENX US, INC. $1,080.00 08/07/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146642
Principal investigator 1 ARGENX US, INC. $375.00 08/07/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146646
Principal investigator 1 ARGENX US, INC. $88.00 08/07/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146656
Principal investigator 1 ARGENX US, INC. $88.00 08/07/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146660
Principal investigator 1 ARGENX US, INC. $56.40 08/04/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144576
Principal investigator 1 ARGENX US, INC. $207.00 08/04/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144579
Principal investigator 1 ARGENX US, INC. $286.50 08/04/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144583
Principal investigator 1 ARGENX US, INC. $4.20 08/04/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144587
Principal investigator 1 ARGENX US, INC. $2.10 08/04/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144590
Principal investigator 1 ARGENX US, INC. $214.80 08/04/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144593
Principal investigator 1 ARGENX US, INC. $13.25 08/04/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144597
Principal investigator 1 ARGENX US, INC. $286.50 08/04/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144601
Principal investigator 1 ARGENX US, INC. $900.00 08/01/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146624
Principal investigator 1 ARGENX US, INC. $2,178.00 08/01/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146627
Principal investigator 1 ARGENX US, INC. $3,000.00 08/01/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146633
Principal investigator 1 ARGENX US, INC. $8,500.00 08/01/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146651
Principal investigator 1 ARGENX US, INC. $2,034.00 08/01/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146664
Principal investigator 1 GlaxoSmithKline, LLC. $11,400.00 08/01/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS RHEUMATOLOGY ASSOCIATES PC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192140627
Principal investigator 1 SANOFI US SERVICES INC. $119.95 07/21/2025 Non-covered Recipient Entity
Arizona Arthritis Rheumatology Research PLLC
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226083167
Principal investigator 1 SANOFI US SERVICES INC. $4,693.00 07/02/2025 Non-covered Recipient Entity
Arizona Arthritis Rheumatology Research PLLC
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226083170
Principal investigator 1 ARGENX US, INC. $107.40 06/18/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144359
Principal investigator 1 ARGENX US, INC. $573.00 06/18/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144363
Principal investigator 1 ARGENX US, INC. $286.50 06/18/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144366
Principal investigator 1 ARGENX US, INC. $5.25 06/18/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144369
Principal investigator 1 ARGENX US, INC. $3.15 06/18/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144372
Principal investigator 1 ARGENX US, INC. $258.00 06/18/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144376
Principal investigator 1 ARGENX US, INC. $85.40 06/18/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144382
Principal investigator 1 ARGENX US, INC. $159.00 06/18/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144385
Principal investigator 1 ARGENX US, INC. $668.50 06/18/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144388
Principal investigator 1 ARGENX US, INC. $35.80 06/18/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144390
Principal investigator 1 ARGENX US, INC. $21.35 06/18/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144393
Principal investigator 1 ARGENX US, INC. $214.80 06/18/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144398
Principal investigator 1 ARGENX US, INC. $517.50 06/18/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144401
Principal investigator 1 ARGENX US, INC. $75.20 06/18/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144405
Principal investigator 1 ARGENX US, INC. $7.70 06/18/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144409
Principal investigator 1 GlaxoSmithKline, LLC. $2,634.00 06/04/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS RHEUMATOLOGY ASSOCIATES PC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192140615
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,435.80 05/14/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223279754
Principal investigator 1 SANOFI US SERVICES INC. $600.00 04/14/2025 Non-covered Recipient Entity
Arizona Arthritis Rheumatology Research PLLC
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226083124
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,105.00 04/02/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223277518
Principal investigator 1 ABBVIE INC. $590.00 03/18/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINICAL RESEARCH SOLUTIONS LLC
M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202464209
Principal investigator 1 Janssen Research & Development, LLC $17,320.00 02/17/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY RE SEARCH PLLC
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175396155
Principal investigator 1 Eli Lilly and Company $48,931.00 02/04/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187880731
Principal investigator 1 Eli Lilly and Company $2,428.59 01/27/2025 Non-covered Recipient Entity
AARA CLINICAL RESEARCH
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187873191